Research programme: therapeutic proteins - Juvena Therapeutics
Alternative Names: Protein therapeutics programme - Juvena TherapeuticsLatest Information Update: 18 Oct 2023
At a glance
- Originator Juvena Therapeutics
- Class Antifibrotics; Antirheumatics; Hepatoprotectants; Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Idiopathic pulmonary fibrosis; Liver disorders; Metabolic disorders; Osteoarthritis
Most Recent Events
- 18 Oct 2023 Early research in Idiopathic pulmonary fibrosis in USA (unspecified route) (Juvena Therapeutics pipeline, October 2023).
- 20 Sep 2022 Early research in Liver disorders in USA (unspecified route)(Juvena Therapeutics pipeline; September 2022)
- 20 Sep 2022 Early research in Metabolic disorders in USA (unspecified route) (Juvena Therapeutics pipeline; September 2022)